Hermetica Superfood Encyclopedia
The Short Answer
Shogaol is a phenolic ketone derived from the dehydration of gingerols during ginger drying or heating, making it more concentrated in dried ginger than fresh. Its primary mechanism involves inhibition of the NF-κB signaling pathway, suppressing downstream pro-inflammatory mediators including TNF-α, IL-6, and prostaglandin E2.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordshogaol benefits
Synergy Pairings5
Shogaol — botanical close-up
Health Benefits
Origin & History
Natural habitat
Shogaol is a bioactive phenolic compound formed via dehydration of gingerols during drying, cooking, or storage of fresh ginger rhizomes (Zingiber officinale). It is primarily extracted from dried ginger roots using solvent extraction methods, with 6-shogaol being the most abundant analog comprising 0.1-0.5% in dried ginger.
“Ginger, the source of shogaols, has been used for over 5,000 years in Ayurveda, Traditional Chinese Medicine, and Unani systems for nausea, digestion, and inflammation. Dried ginger (shunthi/ganjiang) was specifically valued for its warming potency due to shogaol formation during sun-drying, treating 'cold' conditions like arthritis and respiratory issues.”Traditional Medicine
Scientific Research
Human clinical data on isolated shogaol is limited, with most evidence from whole ginger extracts. Raza et al. (2022, PMID: 35087287) showed hematologic improvements in MDS patients using gingerol/curcumin therapy, while Kumar et al. demonstrated anemia improvements in 68 TB patients using 250mg ginger extract BID. No large RCTs or meta-analyses have isolated shogaol alone, with most evidence remaining preclinical.
Preparation & Dosage
Traditional preparation
No established dosage for isolated shogaol exists. Clinical trials used ginger extracts containing 1-5% shogaols: 250mg BID (equivalent to 3-7.5mg 6-shogaol) for anemia/TB support, or 350mg-1.4g/day gingerol preparations for hematologic conditions. Typical research doses suggest 100-500mg/day ginger extract. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Shogaol is a bioactive phenolic compound (not a whole food), so traditional macronutrient/micronutrient profiling does not apply. Key characteristics: Molecular formula C17H24O3 (6-shogaol, the most studied variant), molecular weight 276.37 g/mol. It is a dehydration product of gingerol formed during drying or heating of ginger (Zingiber officinale). Concentration in dried ginger: 6-shogaol typically ranges from 0.5–1.5 mg/g dry weight, significantly higher than in fresh ginger (<0.1 mg/g) where gingerols predominate. Multiple homologs exist: 4-shogaol, 6-shogaol, 8-shogaol, and 10-shogaol, with 6-shogaol being the most abundant and pharmacologically active. Contains an α,β-unsaturated ketone (vanillyl group) responsible for its electrophilic reactivity and bioactivity. Bioavailability: Poor aqueous solubility limits oral absorption; lipophilic nature (logP ~3.5) facilitates membrane permeability. Undergoes extensive first-pass metabolism; primary metabolites include 5-hydroxy-6-shogaol and mercapturic acid conjugates via Michael addition with glutathione. Nanoparticle and lipid-based delivery systems shown to increase bioavailability by 2–4 fold in preclinical models. No fiber, protein, or conventional vitamin/mineral content as it is an isolated phytochemical.
How It Works
Mechanism of Action
Shogaol suppresses inflammatory cascades by blocking NF-κB nuclear translocation, thereby reducing transcription of pro-inflammatory cytokines TNF-α and IL-6, and inhibiting cyclooxygenase-mediated PGE2 synthesis. At a concentration of 5 µM, 6-shogaol demonstrates approximately 90% inhibition of arachidonic acid release from phospholipid membranes, limiting eicosanoid precursor availability. Additionally, shogaol modulates MAPK and PI3K/Akt pathways, contributing to its antioxidant and potential neuroprotective activity through Nrf2 pathway upregulation.
Clinical Evidence
Current evidence for shogaol's benefits derives predominantly from in-vitro cell-culture studies and animal models, with limited randomized controlled trials in humans. Preclinical data consistently show NF-κB inhibition and cytokine suppression, particularly for 6-shogaol, the most studied isoform. Combined gingerol and curcumin formulations in preliminary clinical observations have reported trilineage hematologic improvements including gains in hemoglobin and platelet counts, though sample sizes remain small and study designs lack rigorous controls. Robust human trials isolating shogaol's independent effects at defined doses are needed before firm clinical recommendations can be made.
Safety & Interactions
Shogaol is generally considered safe when consumed through dietary ginger, but isolated high-dose supplementation lacks long-term human safety data. Due to its inhibition of arachidonic acid release and COX pathways, shogaol may potentiate the effects of anticoagulant and antiplatelet drugs such as warfarin, aspirin, and clopidogrel, increasing bleeding risk. Pregnant individuals are advised to exercise caution, as high-dose ginger-derived compounds have been associated with theoretical uterotonic effects in animal models. Individuals on CYP450-metabolized medications, particularly CYP3A4 substrates, should consult a healthcare provider, as ginger phenolics may modestly influence hepatic enzyme activity.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
6-shogaol8-shogaol10-shogaol[6]-shogaoldehydrated gingeroldried ginger phenolicshunthi compoundganjiang bioactive
Frequently Asked Questions
What is the difference between shogaol and gingerol?
Gingerols are the primary pungent compounds in fresh ginger, while shogaols form when gingerols undergo dehydration during drying or cooking, losing a hydroxyl group to form an alpha-beta unsaturated ketone. This structural difference makes shogaols more lipophilic and generally more bioactive, with 6-shogaol showing greater anti-inflammatory potency than 6-gingerol in most in-vitro comparisons. Dried ginger and ginger extracts therefore tend to contain higher shogaol concentrations than fresh root.
What dose of shogaol is needed for anti-inflammatory effects?
In vitro, 6-shogaol achieves approximately 90% inhibition of arachidonic acid release at a concentration of 5 µM, but translating this to a human oral dose is complicated by poor bioavailability and extensive first-pass metabolism. No established clinical dose for isolated shogaol supplements exists, and most human studies use whole ginger extracts standardized to total gingerols and shogaols rather than isolated shogaol. Typical standardized ginger extract doses range from 250 mg to 1000 mg daily, but specific shogaol content per product varies widely.
Can shogaol help with neuroprotection or brain health?
Preclinical research suggests 6-shogaol may exert neuroprotective effects by activating the Nrf2/HO-1 antioxidant pathway and reducing neuroinflammatory markers in microglia, including inhibiting LPS-induced iNOS and COX-2 expression. Animal studies have shown improvements in memory and reduced amyloid-beta aggregation markers, suggesting relevance to neurodegenerative disease models. However, no clinical trials in humans have confirmed these neuroprotective effects for shogaol specifically, so current evidence remains preliminary.
Is shogaol safe to take with blood thinners like warfarin?
Shogaol inhibits arachidonic acid release and suppresses platelet-activating pathways, which may additively increase bleeding risk when combined with anticoagulants such as warfarin or antiplatelet agents like aspirin and clopidogrel. Ginger-derived compounds have been flagged in pharmacokinetic studies for potential CYP2C9 interaction, which is the primary enzyme metabolizing warfarin, potentially altering its plasma levels. Anyone taking anticoagulant therapy should consult their physician before using shogaol-containing supplements and monitor INR values if combination use is unavoidable.
Does shogaol have anticancer properties?
Multiple in-vitro studies demonstrate that 6-shogaol induces apoptosis in cancer cell lines including breast, colorectal, and lung cancer cells, partly through mitochondrial pathway activation involving caspase-3 and caspase-9 and downregulation of anti-apoptotic Bcl-2 proteins. It also inhibits cancer cell migration and invasion by suppressing matrix metalloproteinase MMP-2 and MMP-9 expression via NF-κB blockade. These findings are currently limited to cell culture and rodent tumor models, and no human clinical trials have evaluated shogaol as a standalone anticancer intervention.
What is the bioavailability of shogaol compared to other ginger compounds, and how is it best absorbed?
Shogaol is a dehydrated form of gingerol that forms during ginger heating and drying, offering potentially different absorption kinetics than its precursor. Research suggests shogaol may have enhanced lipophilicity, allowing better penetration across cell membranes and the blood-brain barrier, though direct human bioavailability studies are limited. Consuming shogaol-rich sources (dried or heat-processed ginger) alongside dietary fats may improve absorption, as the compound is fat-soluble.
Is shogaol safe for children, and what age groups can use ginger supplements containing it?
Limited safety data exists specifically for shogaol in pediatric populations, though traditional ginger use in children has a long history of safety at culinary doses. Most clinical evidence for ginger bioactives comes from adult studies, making it prudent to consult a healthcare provider before giving shogaol-containing supplements to children under 12. Pregnant and nursing women should also seek professional guidance due to insufficient human safety data for shogaol specifically.
How strong is the current clinical evidence for shogaol's anti-inflammatory effects in humans versus laboratory studies?
Most evidence for shogaol's anti-inflammatory mechanisms comes from in-vitro and animal studies showing NF-κB inhibition and reduction of inflammatory markers like TNF-α and IL-6; human clinical trials remain sparse and preliminary. The limited clinical data available (such as the mixed-ginger myelodysplastic syndrome study) involves combination treatments, making it difficult to isolate shogaol's specific contribution. Larger, well-designed randomized controlled trials in humans are needed to establish therapeutic efficacy and translate laboratory findings into reliable clinical recommendations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w shogaol curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
